New combo therapy targets hard-to-treat lung cancer in chinese patients

NCT ID NCT05374603

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the combination. The main goal is to see how long the cancer stays under control without growing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Research Site

Beijing, 100021, China
Research Site

Beijing, 100039, China
Research Site

Beijing, CN-100730, China
Research Site

Changsha, 410011, China
Research Site

Chongqing, 400010, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310009, China
Research Site

Jinan, 250021, China
Research Site

Kunming, 650118, China
Research Site

Nanchang, 330006, China
Research Site

Ningbo, 315100, China
Research Site

Shanghai, 200030, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Zhengzhou, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.